These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31595974)

  • 1. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
    Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
    Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
    Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
    Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
    Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
    Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
    Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
    Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
    Huddle BC; Grimley E; Buchman CD; Chtcherbinine M; Debnath B; Mehta P; Yang K; Morgan CA; Li S; Felton J; Sun D; Mehta G; Neamati N; Buckanovich RJ; Hurley TD; Larsen SD
    J Med Chem; 2018 Oct; 61(19):8754-8773. PubMed ID: 30221940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
    Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression.
    Namekawa T; Ikeda K; Horie-Inoue K; Suzuki T; Okamoto K; Ichikawa T; Yano A; Kawakami S; Inoue S
    Int J Cancer; 2020 Feb; 146(4):1099-1113. PubMed ID: 31187490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
    Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
    Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
    Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
    Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
    Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
    PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
    Yoshino J; Akiyama Y; Shimada S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Carcinogenesis; 2020 Jul; 41(6):734-742. PubMed ID: 31665232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
    Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
    Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.